Literature DB >> 17071604

Fas-mediated apoptosis in cholangiocarcinoma cells is enhanced by 3,3'-diindolylmethane through inhibition of AKT signaling and FLICE-like inhibitory protein.

Yabing Chen1, Jianmin Xu, Nirag Jhala, Pritish Pawar, Zeng B Zhu, Liping Ma, Chang-Hyun Byon, Jay M McDonald.   

Abstract

Stimulation of Fas-mediated apoptosis has been promoted as a potential therapy for many cancers, including cholangiocarcinoma. We have previously reported that Fas-resistant, but not Fas-sensitive, cholangiocarcinoma cells are tumorigenic in nude mice. The present studies sought to identify molecular targets that promote Fas-mediated apoptosis in cholangiocarcinoma. We found that Fas-resistant cholangiocarcinoma cells exhibited increased constitutive phosphorylation of AKT compared with Fas-sensitive cells. Increased phosphorylation of AKT was also demonstrated in human cholangiocarcinoma tumors and was evident in a mouse xenograft cholangiocarcinoma model. Furthermore, we found that 3,3'-diindolylmethane (DIM), a vegetable autolysis product, promoted Fas-mediated apoptosis of cholangiocarcinoma cells. DIM inhibited phosphorylation of AKT and activation of FLICE-like-inhibitory-protein (FLIP). Inhibition of phosphatidylinositol 3-kinase/AKT decreased FLIP activation and promoted Fas-mediated apoptosis. By contrast, adenovirus-mediated constitutively activated AKT protected cholangiocarcinoma cells from Fas-mediated apoptosis. Decreased activation of extracellular signal-regulated kinase and nuclear factor-kappaB and increased activation of caspase-3, -8, and -9 were associated with inhibition of AKT and FLIP. These results support AKT and FLIP as potential molecular targets and DIM as a potent compound for cholangiocarcinoma intervention.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17071604      PMCID: PMC1780198          DOI: 10.2353/ajpath.2006.060234

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  47 in total

1.  The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways.

Authors:  T Kataoka; R C Budd; N Holler; M Thome; F Martinon; M Irmler; K Burns; M Hahne; N Kennedy; M Kovacsovics; J Tschopp
Journal:  Curr Biol       Date:  2000-06-01       Impact factor: 10.834

2.  A novel ring-substituted diindolylmethane,1,1-bis[3'-(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia.

Authors:  Rooha Contractor; Ismael J Samudio; Zeev Estrov; David Harris; James A McCubrey; Stephen H Safe; Michael Andreeff; Marina Konopleva
Journal:  Cancer Res       Date:  2005-04-01       Impact factor: 12.701

3.  Agonists of an ecdysone-inducible mammalian expression system inhibit Fas Ligand- and TRAIL-induced apoptosis in the human colon carcinoma cell line RKO.

Authors:  I Oehme; S Bösser; M Zörnig
Journal:  Cell Death Differ       Date:  2006-02       Impact factor: 15.828

4.  Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand.

Authors:  M Jo; T H Kim; D W Seol; J E Esplen; K Dorko; T R Billiar; S C Strom
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

5.  Cholangiocarcinomas express Fas ligand and disable the Fas receptor.

Authors:  F G Que; V A Phan; V H Phan; A Celli; K Batts; N F LaRusso; G J Gores
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

6.  PI3-K/AKT regulation of NF-kappaB signaling events in suppression of TNF-induced apoptosis.

Authors:  M E Burow; C B Weldon; L I Melnik; B N Duong; B M Collins-Burow; B S Beckman; J A McLachlan
Journal:  Biochem Biophys Res Commun       Date:  2000-05-10       Impact factor: 3.575

7.  Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB.

Authors:  L V Madrid; C Y Wang; D C Guttridge; A J Schottelius; A S Baldwin; M W Mayo
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

8.  Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.

Authors:  Jirong Bai; Jianhua Sui; Aram Demirjian; Charles M Vollmer; Wayne Marasco; Mark P Callery
Journal:  Cancer Res       Date:  2005-03-15       Impact factor: 12.701

Review 9.  Cholangiocarcinoma.

Authors:  S A Ahrendt; A Nakeeb; H A Pitt
Journal:  Clin Liver Dis       Date:  2001-02       Impact factor: 6.126

10.  Enhancement of susceptibility to Fas-mediated apoptosis in HL-60 cells through down-regulation of cellular FLICE-inhibitory protein by phosphatidylinositol 3-kinase inhibitors.

Authors:  Gen Kondo; Masayasu Iwase; Hitoshi Watanabe; Makiko Uchida; Sayaka Takaoka; Masaru Ohashi; Daisuke Ito; Masao Nagumo
Journal:  Oncol Rep       Date:  2005-11       Impact factor: 3.906

View more
  25 in total

1.  Activation of checkpoint kinase 2 by 3,3'-diindolylmethane is required for causing G2/M cell cycle arrest in human ovarian cancer cells.

Authors:  Prabodh K Kandala; Sanjay K Srivastava
Journal:  Mol Pharmacol       Date:  2010-05-05       Impact factor: 4.436

2.  Prostate apoptosis response-4 is expressed in normal cholangiocytes, is down-regulated in human cholangiocarcinoma, and promotes apoptosis of neoplastic cholangiocytes when induced pharmacologically.

Authors:  Antonio Franchitto; Alessia Torrice; Rossella Semeraro; Cristina Napoli; Gennaro Nuzzo; Felice Giuliante; Gianfranco Alpini; Guido Carpino; Pasquale Bartolomeo Berloco; Luciano Izzo; Antonio Bolognese; Paolo Onori; Anastasia Renzi; Alfredo Cantafora; Eugenio Gaudio; Domenico Alvaro
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

3.  Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism.

Authors:  Gabriel Frampton; Pietro Invernizzi; Francesca Bernuzzi; Hae Yong Pae; Matthew Quinn; Darijana Horvat; Cheryl Galindo; Li Huang; Matthew McMillin; Brandon Cooper; Lorenza Rimassa; Sharon DeMorrow
Journal:  Gut       Date:  2011-11-07       Impact factor: 23.059

4.  PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy.

Authors:  Kaiyu Yuan; Yong Sun; Tong Zhou; Jay McDonald; Yabing Chen
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

5.  Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.

Authors:  Supak Yothaisong; Hasaya Dokduang; Anchalee Techasen; Nisana Namwat; Puangrat Yongvanit; Vajarabhongsa Bhudhisawasdi; Anucha Puapairoj; Gregory J Riggins; Watcharin Loilome
Journal:  Tumour Biol       Date:  2013-07-06

6.  Conformation and free energy analyses of the complex of calcium-bound calmodulin and the Fas death domain.

Authors:  Jonathan D Suever; Yabing Chen; Jay M McDonald; Yuhua Song
Journal:  Biophys J       Date:  2008-09-26       Impact factor: 4.033

7.  Trifluoperazine regulation of calmodulin binding to Fas: a computational study.

Authors:  Di Pan; Qi Yan; Yabing Chen; Jay M McDonald; Yuhua Song
Journal:  Proteins       Date:  2011-06-07

Review 8.  Targeted regulation of PI3K/Akt/mTOR/NF-κB signaling by indole compounds and their derivatives: mechanistic details and biological implications for cancer therapy.

Authors:  Aamir Ahmad; Bernhard Biersack; Yiwei Li; Dejuan Kong; Bin Bao; Rainer Schobert; Subhash B Padhye; Fazlul H Sarkar
Journal:  Anticancer Agents Med Chem       Date:  2013-09       Impact factor: 2.505

9.  Calmodulin mediates Fas-induced FADD-independent survival signaling in pancreatic cancer cells via activation of Src-extracellular signal-regulated kinase (ERK).

Authors:  Kaiyu Yuan; Gu Jing; Jianfeng Chen; Hui Liu; Kui Zhang; Yuebin Li; Hui Wu; Jay M McDonald; Yabing Chen
Journal:  J Biol Chem       Date:  2011-05-25       Impact factor: 5.157

10.  Pathobiology of biliary epithelia and cholangiocarcinoma: proceedings of the Henry M. and Lillian Stratton Basic Research Single-Topic Conference.

Authors:  Alphonse E Sirica; Michael H Nathanson; Gregory J Gores; Nicholas F Larusso
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.